Institute for Advanced Clinical Trials for Children

Dear I-ACT for Children Friends and Colleagues, ? Over the past seven years, with your collaboration and support, we have made significant strides in strengthening the pediatric clinical trial ecosystem. As we look toward 2025 and beyond, I-ACT for Children stands at a pivotal moment in our commitment to advancing pediatric drug development. ? Pediatric drug development is evolving rapidly, driven by technological advancements and the need for a more streamlined global approach. Recognizing this, I-ACT has been working closely with our European counterpart, conect4children (c4c, https://conect4children.eu), to establish a global alliance of pediatric research sites and experts - enhancing international collaboration and accelerating pediatric drug development. ? In the coming months, c4c will lead this global initiative. While not a merger, I-ACT and c4c will work closely together to explore how I-ACT’s experts and sites can be integrated with c4c’s network, creating a more efficient, globally integrated pediatric research resource. Consolidating I-ACT and c4c activities will bring significant benefits to pediatric drug development stakeholders and, most importantly, to children: ?? ???????????????? ?????? ?????? ?????????????? ? Our priority is to ensure a seamless evolution leveraging the strengths of both organizations. As of April 1, 2025, c4c will be taking the lead in planning a single pediatric research network. Over the coming months, c4c will work with I-ACT experts and sites to establish a shared way of working. ? ??-??????’?? ???????? ?????????? ? As of April 1, 2025, I-ACT will wind down its operations, with c4c becoming the point of contact.?By mid-summer I-ACT’s legal entity will be dissolved. ? To support ongoing access to I-ACT’s pediatric research resources: I-ACT’s current resources and educational materials will remain available through the Critical Path Institute (C-Path) at https://c-path.org. Going forward, I-ACT’s sites will benefit from opportunities arising from c4c’s educational offering at https://conect4children.eu? ?? As a key stakeholder, your engagement will be critical as we move forward together in this transformational initiative. By working collaboratively, we can build a stronger global pediatric research framework—delivering medicines to children safely, efficiently, and faster than ever before. Regards, I-ACT for Children #thenextchapter #collaboration

?? ????. ??.??. ?????????? ?????????? ???????? ???? ?????????? ?????????????? ?????????????? ???? ??-?????? The Institute for Advanced Clinical Trials for Children (I-ACT) announces that Dr. A.J. Allen will step down as Chief Medical Officer, effective March 3, 2025. ? Since joining I-ACT, Dr. Allen has played a pivotal role in advancing our mission to accelerate pediatric drug development and improve access to innovative therapies for children worldwide. His leadership and expertise have been instrumental in strengthening I-ACT’s collaborations with industry, regulators, and research networks, ensuring that the needs of children remain at the forefront of clinical innovation. ? Dr. Allen’s distinguished career has been marked by transformational contributions to pediatric drug development. His unwavering commitment to scientific excellence, regulatory strategy, and patient-centered research has significantly shaped the landscape of pediatric clinical trials, influencing policies and practices that will have a lasting impact on child health. ? We extend our deepest gratitude to Dr. Allen for his dedication and leadership. While he will be greatly missed at I-ACT, we celebrate his remarkable achievements and wish him the very best in his future endeavors. ? ?? Please join us in thanking Dr. Allen for his invaluable contributions to I-ACT and to the broader field of pediatric medicine. ? With appreciation, Vivianna Guzman Executive Director #pediatricleaders

If you haven't had a chance to check it out, tune in to Mary Short as she emphasizes the importance of advocating for Pediatric Research Development. Advocacy is essential; a single voice has the power to bring many together. #nochildleftbehind #pediatricresearch

Don't miss out on this insightful iCAN (International Children's Advisory Network) event featuring Mary Short, a leading expert in pediatric drug development. Learn about the crucial need for advocacy in this vital field. #ICAN #pediatricdrugdevelopment #childrenmatter

??Please take the mere minutes it takes to save lives by contacting your state Representatives. Team Telomere along with 200 other orgs have been advocating for this and it will directly affect #ClinicalTrials in #TBDs I know my child is here because of policies in place that allowed travel to a clinical trial - bone marrow registry - telehealth - and more. ??Call today and the again tomorrow!

I???????????????? ????????. ?????????? ???? ????????! According to recent reports,?Congress is on track to pass an extension of the Pediatric Rare Disease Priority Review Voucher (PPRV) program, with the House of Representatives already passing a bill, known as the "Give Kids a Chance Act," that would extend the program until 2029, providing significant support for the development of treatments for rare pediatric diseases. The proposal appears likely to pass the House and Senate before the holiday break. This vital legislation incentivizes the development of innovative treatments for children with the most rare and devastating pediatric diseases. Please contact your Senators today and urge them to pass the Creating Hope Reauthorization Act ASAP. https://lnkd.in/gN_e6DPQ. #PPRV #raredisease #pediatrics

????????????'?? ?????????????????? ???????? ??-?????? ?????? ????????????????! As we reflect on the past year, we are filled with gratitude for the opportunity to work alongside dedicated professionals like you who share our commitment to improving the lives of children everywhere. May this holiday season bring you joy, peace, and time to rest and recharge with loved ones. We look forward to continuing our work together in the new year, and making even greater strides toward ensuring that all children have access to safe and effective treatments. Thank you for your unwavering support and partnership. Wishing you a happy holiday season and a prosperous new year ahead. Warm regards, The I-ACT for Children Team

?????? ?????? ???????? ?????? ???????????? ?????????????? ???? ???????? ?????? ???????? ??????????????? ??????'?? ??????????, ????'???? ?????? ?????? ??????????????! You can still catch up on all the valuable information by watching the webinar recording. Trust us, you won't want to miss out on this fantastic opportunity to learn from top professionals in the industry. Our webinar featured experts in the field sharing the latest advancements and breakthroughs in the exciting world of Cell and Gene Therapy and the ongoing risks and ethical challenges. As well as hearing firsthand from a parent whose son received Cell and Gene Therapy and what a profound impact it has had on his life. Link to Recording: https://lnkd.in/eTb8TUxQ? #CGT #research #clinicaltrials

?? Webinar Starts Today ?? Science Applications & Ethics of Cell & Gene Therapy December 10, 2024 12 pm ET ? You can still register. https://lnkd.in/ewJrhJFx Hope to see you there! #cellandgenetherapy #ethics #pediatric

?????????????????????? ???? ??-?????? ?????? ???????????????? (????) ?????? ???????????????? ?????????????????? ???????????????? ?????????? ???????????????? ???? ???????????????????? ?????????????????? ???????????????? ???????????? Incredible progress is being made in pediatric clinical trials thanks to innovative partnerships! What an amazing manuscript! It demonstrates how networks have been able to share knowledge and resources to identify potential sites for pediatric clinical trials, ultimately speeding up the trial process and ensuring that more children have access to cutting-edge therapies. This collaboration also emphasizes the importance of establishing communication systems between sponsors and networks early in the trial planning process. Congratulatoins to the authors for their valuable contribution to this important topic. Eva Degraeuwe, Mark Turner, Raes Ann, Laura Persijn, Collin Hovinga, Annelies De Maré, Ricardo Fernandes, and Callie Heaton, MSHS, CCRA. https://lnkd.in/e5Acfb3M #sitenetwork #collaboration #pediatricclinicaltrials